VICTOR: Vericiguat lowers the risk of cardiovascular and all-cause death in patients with heart failure

ESC 2025

Heart Failure

VICTORIA and VICTOR: Vericiguat reduces the risk of both cardiovascular death and HF hospitalizations, as well as all-cause mortality in a broad population of patients with heart failure

Heart Failure

Kidney Tubular Biomarkers Predict Risk of Death and Heart Failure Readmission in Acute Heart Failure

J Am Heart Assoc

Wettersten N, Duff S, Horiuchi Y, van Veldhuisen DJ, Estrella MM, Shlipak MG, Maisel A, Murray PT, Ix JH

doi: 10.1161/JAHA.125.042880

Heart Failure

Vericiguat and mortality in heart failure and reduced ejection fraction: the VICTOR trial

Eur Heart J

Butler J, Fioretti F, McMullan CJ, Anstrom KJ, Barash I, Bonaca MP, Borentain M, Corda S, Teixeira PP, Ezekowitz JA, Gates D, Lam CSP, Lewis EF, Lindenfeld J, Mentz RJ, O'Connor CM, Ponikowski P, Reddy YNV, Rosano GMC, Saldarriaga C, Senni M, Udelson J, Urbinati A, Vlajnic V, Voors AA, Xing A, Patel MJ, Zannad F

doi: 10.1093/eurheartj/ehaf655

Heart Failure

Dapagliflozin in Patients Hospitalized for Heart Failure: Primary Results of the DAPA ACT HF-TIMI 68 Randomized Clinical Trial and Meta-Analysis of Sodium-Glucose Cotransporter-2 Inhibitors in Patients Hospitalized for Heart Failure

Circulation

Berg DD, Patel SM, Haller PM, Cange AL, Palazzolo MG, Bellavia A, Kuder JF, Desai AS, Inzucchi SE, McMurray JJV, O'Meara E, Verma S, Bělohlávek J, Drożdż J, Merkely B, Ogunniyi MO, Drasnar T, Izzo JL, Sarman B, McGinty JE, Ramanathan K, Mulkay AJ, Przybylski A, Ruff CT, O'Donoghue ML, Murphy SA, Sabatine MS, Wiviott SD, DAPA ACT HF-TIMI 68 Trial Committees and Investigators

doi: 10.1161/CIRCULATIONAHA.125.076575

Heart Failure

Blood pressure, safety and clinical efficacy of vericiguat in chronic heart failure with reduced ejection fraction: Insights from the VICTOR trial

Eur J Heart Fail

Mentz RJ, Butler J, McMullan CJ, Wojdyla DM, Anstrom KJ, Barash I, Bonaca MP, Borentain M, Corda S, Ezekowitz JA, Gates D, Lam CSP, Lewis EF, Lindenfeld J, O'Connor CM, Ponikowski P, Reddy YNV, Rosano GMC, Saldarriaga C, Senni M, Teixeira PP, Udelson J, Urbinati A, Vlajnic V, Voors AA, Xing A, Zannad F, VICTOR Study Group

doi: 10.1002/ejhf.70033

Heart Failure

Characteristics and outcomes of patients with heart failure and history of malignancy: Data from Swedish Heart Failure Registry and the National Cancer Register

Eur J Heart Fail

Ameri P, Costa P, Benson L, Stolfo D, Sayour NV, Ljungman C, Butler J, Anker SD, Girerd N, Keramida K, Filippatos G, Lund LH, Lindberg F, Savarese G

doi: 10.1002/ejhf.3775

Heart FailureTherapy and Intervention

Prognostic Value of the Meta-Analysis Global Group in Chronic Heart Failure Risk Score in Patients Undergoing Mitral Valve Transcatheter Edge-to-Edge Repair

J Am Heart Assoc

Nishimura Y, Asami M, Horiuchi Y, Tanaka J, Taniwaki M, Komiyama K, Yuzawa H, Tanabe K, Yamamoto M, Kubo S, Saji M, Izumi Y, Sugiura A, Shimura T, Enta Y, Shirai S, Izumo M, Mizuno S, Watanabe Y, Amaki M, Kodama K, Otsuki H, Naganuma T, Bota H, Ohno Y, Yamawaki M, Ueno H, Nakazawa G, Hachinohe D, Otsuka T, Hayashida K, OCEAN‐Mitral Investigators *

doi: 10.1161/JAHA.125.048383

Heart Failure

Predicted Risk, Preclinical Heart Failure Measures, and Incident Heart Failure: The ARIC Study

JACC Heart Fail

Grant JK, Zhang S, Khan SS, Ozkan B, Blumer V, Nambi V, Echouffo-Tcheugui JB, Pandey A, Blumenthal RS, Ballantyne CM, Selvin E, Matsushita K, Shah A, Coresh J, Ndumele CE

doi: 10.1016/j.jchf.2025.102659

Atrial FibrillationHeart Failure

Plasma Biomarkers Associated With Heart Failure Hospitalization Among Patients With Atrial Fibrillation and Subtypes of Heart Failure

J Am Heart Assoc

Pol T, Lindbäck J, Oldgren J, Alexander JH, Siegbahn A, Wallentin L, Hijazi Z

doi: 10.1161/JAHA.125.045970

Related content

VICTORIA and VICTOR: Vericiguat reduces the risk of both cardiovascular death and HF hospitalizations, as well as all-cause mortality in a broad population of patients with heart failure

Kidney Tubular Biomarkers Predict Risk of Death and Heart Failure Readmission in Acute Heart Failure

Vericiguat and mortality in heart failure and reduced ejection fraction: the VICTOR trial

Dapagliflozin in Patients Hospitalized for Heart Failure: Primary Results of the DAPA ACT HF-TIMI 68 Randomized Clinical Trial and Meta-Analysis of Sodium-Glucose Cotransporter-2 Inhibitors in Patients Hospitalized for Heart Failure

Blood pressure, safety and clinical efficacy of vericiguat in chronic heart failure with reduced ejection fraction: Insights from the VICTOR trial

Characteristics and outcomes of patients with heart failure and history of malignancy: Data from Swedish Heart Failure Registry and the National Cancer Register

Prognostic Value of the Meta-Analysis Global Group in Chronic Heart Failure Risk Score in Patients Undergoing Mitral Valve Transcatheter Edge-to-Edge Repair

Predicted Risk, Preclinical Heart Failure Measures, and Incident Heart Failure: The ARIC Study

Plasma Biomarkers Associated With Heart Failure Hospitalization Among Patients With Atrial Fibrillation and Subtypes of Heart Failure